SomaGenics Advances Wound Healing Program with US Patent Award

Santa Cruz, CA - November, 2019   SomaGenics, Inc. today announced the issue of US Patent No. 10,450,569 entitled “Methods and Compositions of Short Small Hairpin RNAs and microRNAs for Wound Healing.”  The patent covers the Company’s’ therapeutic candidates and combination therapy to treat chronic wounds.

SomaGenics has developed a novel treatment to directly target a physiological defect that obstructs healing of chronic wounds. The Company’s RNA-based therapy, which utilizes a specialized wound dressing, provides slow release of a combination of modified RNAs targeting separate parts of the wound healing pathway.

“Our preclinical data clearly demonstrate an acceleration of healing in an animal model of chronic wound healing compared to controls.  They also support the theoretical mechanism of action, which is the inhibition of key regulators of the wound healing pathway.  The ability to deliver the active therapeutics using a topical dressing provides an additional advantage to the patient in terms of cost, treatment compliance and effectiveness,” commented Dr. Brian Johnston, CEO of SomaGenics.  

SomaGenics’ RNA-based therapeutic platform shows promise as a new treatment modality for chronic diabetic wounds, conditions for which existing treatment options are often ineffective. 

SomaGenics is a privately held biotech company with offices and laboratories located in Santa Cruz, Calif. The Company specializes in developing innovative technologies that focus on RNA molecules as therapeutic agents and targets as well as biomarkers. The company's therapeutic platform includes sshRNA therapeutic candidates for wound healing and viral hepatitis.

Contact: Anne Scholz, 831 426 7700 ext. 17.